{"id":234280,"date":"2026-04-22T07:15:00","date_gmt":"2026-04-22T11:15:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/04\/22\/fda-approves-msds-once-daily-hiv-combo-idvynso\/"},"modified":"2026-04-22T07:50:18","modified_gmt":"2026-04-22T11:50:18","slug":"fda-approves-msds-once-daily-hiv-combo-idvynso","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/04\/22\/fda-approves-msds-once-daily-hiv-combo-idvynso\/","title":{"rendered":"FDA approves MSD\u2019s once-daily HIV combo Idvynso"},"content":{"rendered":"<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/msd-merck-idvynso-fda-approval-hiv-combination-regimen\/\">FDA approves MSD\u2019s once-daily HIV combo Idvynso<\/a><\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/msd-merck-idvynso-fda-approval-hiv-combination-regimen\/\">https:\/\/www.pharmaceutical-technology.com\/news\/msd-merck-idvynso-fda-approval-hiv-combination-regimen\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-04-22 07:15:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.pharmaceutical-technology.com\">www.pharmaceutical-technology.com<\/a><\/p>\n<p>                                    Idvynso is the first non-INSTI, tenofovir-free, two-drug regimen to get the FDA\u2019s blessing. Credit: Tatyana Frolova \/ Shutterstock.com.<\/p>\n<p class=\"drop-cap\">MSD (Merck &#038; Co) has secured a US approval for its two-drug human immunodeficiency virus (HIV) combination therapy, Idvynso (doravirine\/islatravir), as the company looks to secure a slice of the lucrative market.<\/p>\n<p>Once-daily Idvynso was given the US regulatory greenlight based on the results of the Phase III MK-8591A-051 and MK-8591A-052 (NCT05631093; NCT05630755) trials, which found that patients switched from Gilead\u2019s SoC therapy, Biktarvy (bictegravir\/emtricitabine\/tenofovir alafenamide), maintained viral suppression at a non-inferior level when taking Idvynso daily.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/img\/globaldata_marketing_solutions_logo.svg\" alt=\"\"\/><\/p>\n<h4> Discover B2B Marketing That Performs <\/h4>\n<p>\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n<p>\n\t\t\t\t\t\t\tFind out more <span><\/span><\/p>\n<p>This means that American patients who are virologically suppressed and on a stable antiretroviral (ART) regimen can now be switched to Idvynso, provided they have not previously experienced virologic treatment failure or doravirine resistance.<\/p>\n<p>According to Anaelle Tannen, infectious disease analyst at GlobalData, Idvynso\u2019s regulatory greenlight reflects a broader shift in the HIV treatment landscape away from traditional three-drug combinations toward simpler, potentially more tolerated options.<\/p>\n<p>Currently, the HIV market is dominated by Gilead\u2019s three-drug regimen, Biktarvy, though GSK\u2019s dual therapy, Dovato&#8230;<\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/msd-merck-idvynso-fda-approval-hiv-combination-regimen\/\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA approves MSD\u2019s once-daily HIV combo Idvynso https:\/\/www.pharmaceutical-technology.com\/news\/msd-merck-idvynso-fda-approval-hiv-combination-regimen\/ Publish Date: 2026-04-22 07:15:00 Source Domain: www.pharmaceutical-technology.com&#8230;<\/p>\n","protected":false},"author":1,"featured_media":234281,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.pharmaceutical-technology.com\/wp-content\/uploads\/sites\/24\/2026\/04\/shutterstock_2486304439.jpg","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-234280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/234280"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=234280"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/234280\/revisions"}],"predecessor-version":[{"id":234282,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/234280\/revisions\/234282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/234281"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=234280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=234280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=234280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}